NCT07037433: Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- State
- Under way
- Phase
- Phase 3
- People
- 12,800 planned
- Started
- 25 Jul 2025
- Primary completion
- 30 Jun 2028
- Arms
- Maridebart Cafraglutide
- Results
- None posted
- 25 Jun 2025: Trial registered
- 25 Jul 2025: Trial started